healthy skin

beauty beyond the

surfaceEmme, plus-size model and

wellness advocate, prepares you to put your best face forward

An Independent supplement by medIAplAnet to usA todAy

Inner beautyHow to love the skin you’re in

early detectionthe link between the sun’s rays and cancer

eczema awarenessthe calm after the chronic itch

Hey dry skin, I found real relief.Get coupons and find a store at amlactin.com

Follow us on Twitter!

ph

oto

cr

ed

it: N

its

aN

ta

l p

ho

tog

ra

ph

y a

Nd

Ma

ke

up

: ali

so

N r

afa

ell

e c

os

Me

tic

s

for a grEat complExion

healthy skinhealthy skinhealthy skinfor a grEat

3tips

2 · mArcH 2011 An Independent supplement by medIAplAnet to usA todAy

“picture the adolescent that has severe acne, the young man who no longer feels comfortable going to the gym, the child that has deformities …”

ChallenGesskin disease is more prevalent than anyone ever imagined and carries with it serious medical consequences.

let your skin reflect the beauty within you

at any given time,  one in ev-ery three peo-ple  in the Unit-ed States suffers from a skin dis-ease. The Ameri-

can Academy of Dermatology As-sociation and the Society for In-vestigative Dermatology com-missioned a study by the Lewin Group to quantify the burden of skin disease.  This study shows that skin disease is more prev-alent than anyone ever imag-ined—and carries serious medi-cal and financial consequences. This study analyzed 22 skin dis-eases and found that the direct costs (prescription drugs, hospi-tal and doctor visits, nursing care and over the counter products) totaled $29.1 billion. The total in-direct costs associated with lost productivity of not being able to work and taking time for doctors’ visits totaled $10.2 billion.

Cost is not the only issue with

skin diseases. Since most skin diseases are visible, there are psy-chological issues that may se-verely affect quality of life. Pic-ture the adolescent that has se-vere acne, the young man who no longer feels comfortable going to the gym to work out because of skin rashes, the child who has deformities and others that have chronic blistering or are unable to sweat.

This supplement highlights a few of the more common skin dis-eases: rosacea, eczema and skin cancer, as well as the importance of loving the skin you’re in. There are thousands of other skin dis-eases, some that are relatively easy to treat and curable. Some are life threatening. Others are very rare, have few treatment options and patients will live with them their entire life.

You’re not aloneMany patients with skin dis-ease may think they are the on-

ly ones affected and feel very alone if they don’t know anyone else with their disease. There is support available in many dif-ferent ways through patient advocacy groups. Many of the members of the Coalition of Skin Diseases have patient ed-ucation meetings, online sup-port groups and disease specific information on their websites. Educating yourself will give you more information about treatments available and sug-gestions about living with your disease. Their websites will give you additional resources that may be helpful.

The Coalition of Skin Diseases (CSD) is a voluntary coalition of patient advocacy groups address-ing the needs and concerns of mil-lions of people whose lives are af-fected by skin disease. For a list of members of the Coalition of Skin Diseases and how to contact them for more information, go to www.coalitionofskindiseases.org.

Judy Jonespresident, coalition of skin diseases

healthy skiN 3rd editioN, March 2011

managing Director: Jon silvermanjon.silverman@mediaplanet.comEditorial manager: Jackie mcdermottjackie.mcdermott@mediaplanet.com

responsible for this issue:publisher: catherine marengocatherine.marengo@mediaplanet.comBusiness Developer: paul Herron paul.herron@mediaplanet.com Designer: missy Kaykomissy.kayko@mediaplanet.comcontributors: Faye brookman, Avery Hurt, Judy Jones, perry robins, m.d.

Distributed within: usA todAy, march 2011this section was created by mediaplanet and did not involve usA todAy or its editorial departments.

check out the interview with plus-size model and health, wellness advocate, emme.

We recoMMeNd

pAge 9

mediaplanet’s business is to create new customers for our advertisers by providing readers with high-quality editorial content that motivates them to act.

a far too common cancer p. 4learn all about skin cancer prevention from the skin cancer Foundation and dr. perry robins.

Please find a cure for Pachyonychia Congenita

www.pachyonychia.org

A Call To Action For Healthy Skin

Pachyonychia Congenita Project

Pachyonychia Congenita (PC) is a ultra rare genetic skin disorder characterized by painful calluses on the soles of the feet, thickened nails and cysts. PC Project seeks treatments and a cure for this debili-tating disorder through (a) an international patient registry (IPCRR) which provides free consultations and genetic testing and (b) sponsorship of the International PC Consortium (IPCC) which includes both scientists and physicians. PC Project initiated the first siRNA clinical trial for skin. www.pachyonychia.org • 877.628.7300

Cutaneous Lymphoma Foundation

Do you have a persistent rash or abnormal skin lesions? Cutaneous T-cell lymphoma (CTCL) is a rare and treat-able form of blood cancer that typically presents first as a rash, lesion or plaque on the skin. Since 1998, the Cuta-neous Lymphoma Foundation has been helping patients, caregivers and physicians improve CTCL diagnosis and treatment while offering a wide range of programs, sup-port and resources. A stubborn skin irritation may turn out to be CTCL. Visit www.clfoundation.org and talk to your doctor to learn more about CTCL, its symptoms and how to get help.www.clfoundation.org • 248.644.9014

Fiona is one of over 10,000 people with a port wine birthmark that results in Sturge-Weber syndrome which affects the eye, brain and skin causing glaucoma, seizures and other secondary health issues. Since 1987, The Sturge-Weber Foundation improves the quality of life for children and adults like Fiona around the world and for all people with a birthmark. We participate in collaborative education, advocacy and translational research to promote medical manage-ment and to identify the cause. www.sturge-weber.orgswf@sturge-weber.org • 1-800-627-5482

UVSunSense Introduced in the United States and distributed in over a dozen countries, UV-SunSense™ is a dispos-able wristband that is a reliable means to moni-tor exposure to harmful UVA and UVB rays for both children and adults. UVSunSense™ wristbands provide users with a simple sun-sensitive gauge through color change. It alerts

the user when they need to reapply sunscreen, and when to get out of the sun. This wristband works with any sun-screen, SPF 15 and above, and it is made from waterproof material so it will always work, no matter where you are.www.uvsunsense.com

PHYTO-C Pro-Heal Serum is the original patented formula by Mostafa Omar, Ph.D. (Patent# US 6,793,449 B2), providing extraordinary antioxidant protection against Ultraviolet (UV) damage by combining L-Ascorbic Acid (Vitamin C), Vitamins A & E and stabilized Olive Leaf Extract. In addi-tion, it contains anti-inflammatory and healing properties that improve the immune system and help to heal Rosacea and reduce Eczema symp-toms. PhytoCeuticals, Inc. is estab-

lished by Dr. Mostafa Omar, the inventor of stabilized L-Ascorbic Acid in the United States with awarded grants by National Cancer Institute (NCI) for “Prevention of UV Photoinjury in Skin by Antioxidants”, and “Photoprotection of Skin by Topical Selenium” since 1995. Please contact 1-877-4-PHYTOC or visit www.phyto-ceutical.com for more information.

Phytoceuticals (Pro-Heal Serum)

pAId For by AdVertIsers

Xeroderma Pigmentosum Family Support Group

The XP Family Support Group is dedicated to improving the quality of life of those affected with Xeroderma Pigmentosum through education and support services, researching effective treatments, and ultimately finding a cure. Xeroderma Pigmentosum (or XP) is a rare inherited disease affecting both males and females. It causes a person to be extremely sensitive to the damaging effects of ultraviolet radiation. Undiagnosed and untreated, XP can lead to the early onset of skin cancer and blindness. In addition, approximately 20% of people with XP also develop progressive neurological disease.www.xpfamilysupport.org • 916-379-0741

4 · mArcH 2011 An Independent supplement by medIAplAnet to usA todAy

insiGhtQuestion: Why is it imperative to check your skin frequently for signs of skin cancer?answer: If diagnosed early, it is one of the easiest cancers to treat.

a far too common cancer

skin cancer is the most common of all cancers, afflict-ing more than two million Americans each year, a number that is rising rapidly.

It is also one of the easiest cancers to treat successfully, if diagnosed early. When allowed to progress, however, skin cancer can result in disfigurement and even death.

That is why it is imperative to check your skin frequently for signs of skin cancer. Skin self-exams should be performed once a month, in addition to an annual full-body skin exam by your physician. A skin self-exam involves systematical-ly examining your entire body for skin changes that could be warn-ing signs of the most common skin cancers (basal and squamous cell carcinomas as well as melanoma, the deadliest form of skin cancer).

During your self-exam, note any changes in your skin, such as in-creases in size or changes in the shape of any growth, spot, sore, mole or lesion. If your skin shows any warning signs of skin cancer, consult your physician. Also be on the lookout for moles that appear

after age 21. Any new skin growth, beauty mark, mole, brown spot, wound, or sore that doesn’t heal can be cause for concern. For a complete self-exam how-to guide, visit www.SkinCancer.org/Self-Examination.

A self-exam should not replace an annual skin exam. Everyone should see a physician, prefer-ably one who specializes in dis-eases of the skin, once a year, or more often if you have a history of skin cancer. If you do not have access to a dermatologist, look for skin cancer screenings in your ar-ea. The Skin Cancer Foundation’s Road to Healthy Skin Tour, pre-sented by AVEENO and Rite Aid, will begin its fourth year on the road next month. The Tour pro-vides free skin cancer screen-ings and valuable information to thousands of people around the country. Over the past three years, 300 dermatologists have volun-teered for the tour, collectively examining more than 10,000 pa-tients in our fully equipped, cus-tomized RV. To find out if the Tour will be in your area, visit www.SkinCancer.org/Tour.

The risks of developing danger-ous skin cancers can be dramatical-

ly and easily reduced through edu-cation, behavior modification, and early detection. Since its inception in 1979, The Skin Cancer Founda-tion has always recommended us-ing a sunscreen with an SPF 15 or higher as one important part of a complete sun protection regimen. Sunscreen alone is not enough,

however. Read our full list of skin cancer prevention tips below.

the skin cancer foundation’s prevention guidelines

■■ Seek the shade, especially between 10 AM and 4 PM.

■■ Do not burn.■■ Avoid tanning and UV tanning

booths.■■ Cover up with clothing, includ-

ing a broad-brimmed hat and UV-blocking sunglasses.

■■ Use a broad spectrum (UVA/UVB) sunscreen with an SPF of 15 or high-er every day. For extended outdoor activity, use a water-resistant, broad spectrum (UVA/UVB) sunscreen with an SPF of 30 or higher.

■■ Apply one ounce (two table-spoons) of sunscreen to your entire body 30 minutes before going out-side. Reapply every two hours or im-mediately after swimming or ex-cessive sweating.

■■ Keep newborns out of the sun. Sunscreens should be used on ba-bies over the age of six months.

■■ Examine your skin head-to-toe every month.

■■ See your physician every year for a professional skin exam.

A Daily SunCare Company• Body and Hand Wash with BUILT IN Sunscreen All in One!• SPF 15 Broad Spectrum Sunscreen, protects you from UVA and UVB sun exposure.• Reduce YOUR risk of getting skin cancer by fighting it DAILY.• Anti- Aging! • Non- Greasy!www.solise.com

PMS 7455 PC

PMS 128 PC

K/O WHITE

SCF SEAL SUNSCREEN (PROCESS COLORS)

SPECIFICATIONS SKIN CANCER FOUNDATION SEAL

COMPANY/DIVISION: SKIN CANCER FOUNDATION

CONTACT INFO: 245 Fifth Avenue SUITE 1403 NY,NY 10016

T 212.725.5176 F 212.725.5751 info@skincancer.org

PRODUCT: SEAL

DATE: 09/14/05

SIZE: U.S.A.:

FILE NAME: SCF SEAL SUNSCREEN

PROGRAM : ADOBE ILLUSTRATOR CS

FONTS: AVENIR LIGHT, AVENIR ROMAN, GILL SANS BOLD CONDENSED

COMMENTS:

PMS 7455 U or 7455 C

PMS 128 U or PMS 129 C

K/O WHITE

SCF SEAL SUNSCREEN (SPOT COLORS)

Note: Must use fonts provided by SCF on disk “SKIN CANCER” K/O TO WHITE“FOUNDATION” K/O TO WHITESUN ARCS: PMS 128 U or 129C“RECOMMENDED” & BACKGROUND: PMS 7455“SUNSCREEN” COPY: PMS 7455

“SKIN CANCER” K/O TO WHITE“FOUNDATION” K/O TO WHITESUN ARCS: PMS 128 PC“RECOMMENDED” & BACKGROUND: PMS 7455 PC“SUNSCREEN” COPY: PMS 7455 PC

Note: SEAL must be no smaller than 1/2 inch width

WHEN PRINTINGNO WHITE BEHIND “RECOMMENDED”

WHEN PRINTINGNO WHITE BEHIND “SUNSCREEN” COPY

news

know your facts for early preventionskin cancer is the most common form of cancer in the United states. more than 3.5 million skin can-cers in over two million people are diagnosed an-nually.

Actinic keratosis is the most common precancer; it affects more than 58 million Ameri-cans. Approximately 65 per-cent of all squamous cell car-cinomas arise in lesions that previously were diagnosed as actinic keratoses. In patients with a history of two or more skin cancers, 36 percent of bas-al cell carcinomas arise in le-sions previously diagnosed as actinic keratoses.

Basal cell carcinoma (BCC) is the most common form of skin cancer; an estimated 2.8 million are diagnosed annual-ly in the US. BCCs are rarely fa-tal, but can be highly disfigur-ing if allowed to grow.

Squamous cell carcinoma (SCC) is the second most com-mon form of skin cancer. An estimated 700,000 cases are diagnosed each year in the US, resulting in approximately 2,500 deaths.

credit: skin cancer Foundation

perry robins, mDprofessor emeritus of dermatology and former chief of the Mohs Micrographic surgery unit, New york university Medical center

“the risks of developing dangerous skin cancers can be dramatically and easily reduced through education, behavior modification and early detection.”

Drink watEr for gooD skin

hYDration

Drink watEr

1tip

a far too common cancer

Our sunscreens provide protection from UVA radiation which causes photoaging and is

linked to aggressive skin cancers. Dermatone’s transparent zinc oxide formula with Z-Cote® blocks UVA as well as UVB and is invisible on the skin. You get the benefits of Zinc over chemical sunscreens. Zinc has 300 years of use with a remarkable safety record. Z-Cote is completely photostable, providing protection that

lasts. Dermatone’s formulas pass stringent testing for sweat and water proofing. Our sunscreen is recommended by Dermatologists and provides safe, effective skin protection for the outdoor enthusiast both in winter and summer. Dermatone’s SPF 36 Z-Cote lotion is ideal for warmer weather. Dermatone

SPF 30 Lips ‘n Face protector tin is optimal for cold weather providing frostbite and windburn protection plus sunscreen. Dermatone is the official sunscreen of the U.S. Ski Team and U.S Snowboarding.

www.dermatone.com(800) 451-7096

Founded in 1981, Dermatone® develops premium sunscreen formulations for optimal skin protection for the outdoor enthusiast.

MsF USA Today 03-2011 2/25/11 1:23 PM Page 1

6 · mArcH 2011 An Independent supplement by medIAplAnet to usA todAy

news

the maddening itcht

he skin rash known as eczema can be maddening—enough to drive otherwise calm, sane people right up the wall. Long-

lasting relief is possible, though.Eczema is increasingly com-

mon. Between 15 and 20 percent of the population—some estimates are even higher—suffers from this irritating condition. It is especial-ly common in children but occurs at all ages. Eczema is character-ized by rough patches of inflamed skin that itch with a vengeance. Scratching just makes it itch more, creating an especially vicious cycle.

No one knows exactly what causes eczema. In some cases the inflammation is set off by an over-zealous immune system. There seems to be a genetic component for some people, and some sufferers have skin that is just not very good at maintaining its barriers—keep-ing moisture in and irritants out, explains Peter Lio, MD, assistant

professor of clinical dermatology and pediatrics Northwestern Uni-versity School of Medicine.

Many things can trigger an out-break of eczema in those who are prone to it. Long hot baths or show-ers, sweating, harsh soaps or house-hold cleansers, and wool fabrics are common triggers. Stress can also be a trigger.

put it to sleepThough eczema cannot be cured, only managed, Lio says that is not

as dismal as it sounds. “The coolest thing I have discovered is that when we get eczema under control with an aggressive, proactive approach, most patients go into something like a re-mission,” he says. Breaking the cycle of itching, scratching, worse itching, more scratching, seems to send the condition into a quiet phase.

For those with mild outbreaks, this can often be accomplished by taking a few easy steps:

■■ Use a good moisturizer several times a day.

■■ Try not to scratch. When you feel the need to scratch, add moisturizer instead, Lio suggests.

■■ Use over the counter corticoste-roids, if necessary, to control the in-flammation and itching. Used as di-rected—during outbreaks, not dai-ly—these medications are safe and effective.

wrapping it upWhen these measures are not enough, doctors will often use a wet wrap. The effected area is thorough-ly moisturized, then wrapped in damp bandages. This blocks out ir-ritants and gives the skin a chance to absorb moisture. It also reduces itching and prevents scratching. Lio has found that wet wraps are often enough to send eczema into remis-sion. But if that doesn’t do the trick, prescription medications, such as stronger corticosteroids and im-munomodulators are available. For more information please visit: www.nationaleczema.org.

Avery Hurt

editorial@mediaplanet.com

QuestioN & aNsWer

■■ how do you get eczema and is it contagious?

Eczema has a genetic basis. Our genes tell our skin how it

will be made. Eczema is not conta-gious. Secondary bacterial infec-tions in the skin can be contagious.

■■ how do you treat eczema and is there a cure?

The most important means of treating eczema is with

education about the condition it-self. Learning the best methods for bathing, avoiding drying soaps, using lubrication and con-trolling itching are cornerstones of management. When infec-tions develop, these should be treated appropriately.

■■ what are the signs and symptoms?

Eczema is characterized by dry, itchy skin that comes

and goes over time. The patient affected with eczema may de-scribe an “itch that rashes” as the itch will herald the onset of a flare of the dermatitis. Small children have red patches on the face and extremities while older children get thickened dry patches in front of the elbows and behind the knees.

■■ is eczema biased to age, gender or race?

All races and both genders may be affected. Most ecze-

ma patients have dermatitis with-in the first year of life. Up to 17 per-cent of school children in the U.S. have some form of eczema.In countries where hygiene is poor, eczema prevalence is re-duced. Parents are encouraged to see a dermatologist early on.

VicioUs cYclEleft: Eczema on a 3-year-old’s ankle. right: Eczema on the back of a 7-year-old’s legs.NatioNal EczEma associatioN

adelaide a. hebert, mDprofessor of dermatology and pediatrics, the university of texas Health sciences center at Houston

“between 15 and 20 percent of the population—some estimates are even higher—suffers from this irritating skin condition.”peter lio, mDassistant professor of clinical dermatology and pediatrics, Northwes-tern university school of Medicine

clEansE skin twicE DailY

clEansE skin twicE DailDailD YailYail

2tip

DESONATE® (desonide) Gel for topical use only

Initial U.S. Approval: 1972

BRIEF SUMMARYCONSULT PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE Desonate is indicated for the treatment of mild to moderate atopic

dermatitis in patients 3 months of age and older. Patients should be instructed to use Desonate for the minimum amount of

time as necessary to achieve the desired results because of the potential for Desonate to suppress the hypothalamic-pituitary-adrenal (HPA) axis [see Warnings and Precautions (5.1)]. Treatment should not exceed 4 consecutive weeks [see Dosage and Administration (2)].

4 CONTRAINDICATIONS Desonate is contraindicated in those patients with a history of

hypersensitivity to any of the components of the preparation.

5 WARNINGS AND PRECAUTIONS5.1 Effects on Endocrine System Systemic absorption of topical corticosteroids can produce reversible

hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for clinical glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of the topical corticosteroid.

The effect of Desonate on HPA axis function was investigated in pediatric subjects, 6 months to 6 years old, with atopic dermatitis covering at least 35% of their body, who were treated with Desonate twice daily for 4 weeks. One of 37 subjects (3%) displayed adrenal suppression after 4 weeks of use, based on the cosyntropin stimulation test. As follow-up evaluation of the subject’s adrenal axis was not performed, it is unknown whether the suppression was reversible [see Use In Specific Populations (8.4) and Clinical Pharmacology (12.2)].

Pediatric patients may be more susceptible than adults to systemic toxicity from equivalent doses of Desonate due to their larger skin surface-to-body mass ratios [see Use In Specific Populations (8.4)].

Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression. Factors that predispose a patient using a topical corticosteroid to HPA axis suppression include the use of more potent steroids, use over large surface areas, use over prolonged periods, use under occlusion, use on an altered skin barrier, and use in patients with liver failure.

An ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression. If HPA axis suppression is documented, an attempt should be made to gradually withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids.

Cushing’s syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids.

Use of more than one corticosteroid-containing product at the same time may increase the total systemic corticosteroid exposure.

5.2 Local Adverse Reactions with Topical Corticosteroids Local adverse reactions may be more likely to occur with occlusive use,

prolonged use or use of higher potency corticosteroids. Reactions may include skin atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria. Some local adverse reactions may be irreversible.

5.3 Concomitant Skin Infections If concomitant skin infections are present or develop during treatment,

an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of Desonate should be discontinued until the infection is adequately controlled.

5.4 Skin Irritation If irritation develops, Desonate should be discontinued and appropriate

therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing.

6 ADVERSE REACTIONS Because clinical trials are conducted under widely varying conditions,

adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In controlled clinical studies of 425 Desonate-treated subjects and 157 Vehicle-treated subjects, adverse events occurred at the application site in 3% of subjects treated with Desonate and the incidence rate was not higher compared with vehicle-treated subjects. The most common local adverse events in Desonate treated subjects were application site burning in 1% (4/425) and rash in 1% (3/425) followed by application site pruritus in <1% (2/425).

Adverse events that resulted in premature discontinuation of study drug in Desonate treated subjects were telangiectasia and worsening of atopic dermatitis in one subject each. Additional adverse events observed during clinical trials for patients treated with Desonate included headache in 2% (8/425) compared with 1% (2/157) in those treated with vehicle.

The following additional local adverse reactions have been reported infrequently with topical corticosteroids. They may occur more frequently with the use of occlusive dressings, especially with higher potency corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, secondary infection, skin atrophy, striae, and miliaria.

© 2010, Intendis, Inc. All rights reserved. June 2010Manufactured by Contract Pharmaceuticals Limited, Buffalo, NY 14213

Distributed by:

Morristown, NJ 07962

6706903BS 09-0081The Desonate logo is a registered trademark of Intendis, Inc. Covered by US Patent No. 6,387,383

mArcH 2011 · 9An Independent supplement by medIAplAnet to usA todAy

inspiration

emme: loving the skin you are in■■ Question: we’ve all made

mistakes in our youth—can we escape our “skin sins”?

■■ answer: As emme shows us, there are steps we can take to im-prove our complexions.

Supermodel Emme helps people feel better about their body image through talk shows, books, lec-tures and the internet, including her new site—Emmenation.com.

“I created Emmenation.com to advise women about facing life challenges and how to feel good about themselves,” says the 47-year-old mother of a daughter, Toby.

Emme knows challenges—not only from fighting stereotypes to succeed as a plus-sized model, but also from battling Stage II Hodg-

kin’s disease in 2007 (she is now cancer free). Through it all, she’s learned to overcome past mistakes in order to move forward.

That’s been especially the case with her skin. Like many women her age, Emme committed sun sins in her youth including using a re-flector to boost her tan.

“I grew up in Saudi Arabia. I’m embarrassed to admit it, but we used baby oil and iodine when we went to the beach,” she recalls. “When we were younger, we didn’t make the connection to sun and wrinkles later in life,” adds Emme.

outer beauty reflects inner healthAlthough she was relatively compliant in washing her face, like many women she also ad-

mitted to occasionally skipping makeup removal before going to bed. A glowing complexion is symbiotic with modeling and Emme began to worry if all of the sun damage from her youth could catch up with her career.

She became further obsessed with her health and appearance after her bout with cancer. She started seeking natural and or-ganic products and eliminated chemicals and dyes. She linked what she ingested and the im-pact that had on her health and skin, vowing to get healthier by doing everything from drinking more water to researching how she could slow down the aging process.

That directed her to the nu-trient lutein as a way to protect,

restore and hydrate her skin. Emme has partnered with Flor-aGLO brand lutein, an ingredi-ent in many vitamins, as well as functional foods and bever-ages. “I start my day by taking a vitamin with FloraGLO Lutein to make sure I keep my skin look-ing its best,” Emme says.

“Most Americans are con-cerned with premature aging. Our desire for healthy, younger-looking skin is greater than ev-er because our outer appearance is a reflection of our inner health and we all want to feel good and look young,” she said. “And we all want to feel good and look as young as we can.”

FAye BrookmAn

editorial@mediaplanet.com

to keep her skin healthy and looking youthful, Emme takes a vitamin with FloraGLO Lutein as part of her daily beauty routine. A natural antioxidant, lutein pro-tects, restores and hydrates skin. FloraGLO is one of her partners in EmmeNation. See www.floraglo lutein.com for more information.Emme is a paid FloraGLO spokesper-son and currently takes and eye vita-min with FloraGLO.

Emmeplus-size model

10 · mArcH 2011 An Independent supplement by medIAplAnet to usA todAy

lifeline skin care’s comprehensive approach uses the latest developments in stem cell technologies to bring you these breakthrough products that deliver important anti-aging benefits:

Hydrates for firmer skin appearance. reduces the appearance of fine wrinkles. evens skin texture. defends against free radicals. results in firmer, smoother. healthier looking skin.

news

the rosy glow of rosacea■■ Question: what did w. c.

Fields, princess di, and rembrandt have in common?

■■ answer: they all suffered from rosacea.

Fields’ trademark bulbous, red nose and Diana’s charming blush were both hallmarks of a frustrating and often embarrassing condition known as rosacea (pronounced rose-ay-shuh). Rosacea is an increasing-ly common skin disorder—as many as 14 million Americans suffer from the condition—that appears as rosy red patches primarily on the cheeks, nose, chin, or forehead. It typically develops when people are in their 30s, 40s or 50s. It often comes and goes, and sometimes goes into re-mission. However, when severe, it can result in visible blood vessels, a noticeable thickening of the skin, and a bumpy swollen nose.

not life-threateningCertain triggers tend to set off a bout of rosacea. Exposure to sun or wind, emotional stress, heavy exercise, al-cohol, and hot, humid weather are all common triggers. Even though rosacea is not life-threatening, the fact that it changes your appear-ance—and not always with the del-icacy of Princess Diana—can make it a psychologically challenging condition. Though alcohol is a trig-ger for many people, rosacea is not an indication of alcoholism. How-ever, the association with alcohol, perpetuated by Fields, can make the

problem even more embarrassing.

managing the glowRosacea is a poorly understood con-dition and there is no cure. However, it can often be managed with care-ful choices. The National Rosacea Society advise a few basic measures to keep outbreaks to a minimum:

■■ Use sunscreen and wear a broad-brimmed hat when outdoors.

■■ Stay in a cool, air-conditioned en-vironment on hot, humid days.

■■ Use a moisturizer daily, especial-ly in cold weather.

■■ Avoid very hot beverages and

very spicy food.■■ Exercise frequently for short pe-

riods rather than for long stretches at a time.If these measures are not enough, your doctor can prescribe medi-cations that will help control the outbreaks.

Because rosacea is not well-known, people often make incor-rect assumptions when they notice an acquaintance or a colleague with an outbreak. It can be very helpful to take the time to explain to them that your appearance is due to a skin condition. It is not contagious, is not caused by poor hygiene or excessive drinking, and will not affect your ability to work. A little candor can do a lot to ease the psychological dis-tress of rosacea.

Avery Hurt

editorial@mediaplanet.com

■■ what causes rosacea?The course of rosacea over time varies from person to person, with many people noticing pe-riodic flares of both the visible signs and symptoms of the dis-order. Common environmental factors that do not cause rosa-cea itself, but tend to trigger a rosacea flare in many people are exposure to higher tem-peratures, such as on a hot day outdoors or after exercise or sauna use, and eating foods or drinking liquids that tend to dilate blood vessels in the skin, such as hot liquids (eg hot cof-fee or tea) or alcohol, especially red wine.

James Q. Del rosso, Do, faocDclinical professor of dermatology, touro university college of osteopathic medicine

rejuvenation for Your skin

help rescue skiN froM sigNs of agiNg

www.lifelineskincare.com

QuestioN & aNsWer

moistUrizE DailY

moistUrizEDailDailD YailYail

3tip

For Dermatologic Use Only–Not for Ophthalmic, Oral, or Intravaginal Use

Rx onlyBRIEF SUMMARY

CONSULT PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION

INDICATIONS AND USAGEFINACEA Gel, 15%, is indicated for topical treatment of inflammatory papules and pustules of mild to moderaterosacea. Although some reduction of erythema which was present in patients with papules and pustules ofrosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papulesand pustules has not been evaluated. Patients should be instructed to avoid spicy foods, thermally hot foods anddrinks, alcoholic beverages and to use only very mild soaps or soapless cleansing lotion for facial cleansing.

CONTRAINDICATIONSFINACEA Gel, 15%, is contraindicated in individuals with a history of hypersensitivity to propylene glycol or anyother component of the formulation.

WARNINGSFINACEA Gel, 15%, is for dermatologic use only, and not for ophthalmic, oral or intravaginal use.There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has notbeen well studied in patients with dark complexion, these patients should be monitored for early signs ofhypopigmentation.

PRECAUTIONSGeneral: Contact with the eyes should be avoided. If sensitivity or severe irritation develops with the use of FINACEAGel, 15%, treatment should be discontinued and appropriate therapy instituted.In a transgenic mouse study, chronic use of FINACEA Gel led to an increased number of animals with papillomasat the treatment site (see PRECAUTIONS: Carcinogenesis, Mutagenesis, and Impairment of Fertility). Theclinical relevance of the findings in animal studies to humans is not clear.Information for Patients: Patients using FINACEA Gel, 15%, should receive the following information andinstructions:• FINACEA Gel, 15%, is to be used only as directed by the physician.• FINACEA Gel, 15%, is for external use only. It is not to be used orally, intravaginally, or for the eyes.• Cleanse affected area(s) with a very mild soap or a soapless cleansing lotion and pat dry with a soft towel

before applying FINACEA Gel, 15%. Avoid alcoholic cleansers, tinctures and astringents, abrasives andpeeling agents.

• Avoid contact of FINACEA Gel, 15%, with the mouth, eyes and other mucous membranes. If it does come incontact with the eyes, wash the eyes with large amounts of water and consult a physician if eye irritation persists.

• The hands should be washed following application of FINACEA Gel, 15%. • Cosmetics may be applied after FINACEA Gel, 15%, has dried.• Skin irritation (e.g., pruritus, burning, or stinging) may occur during use of FINACEA Gel, 15%, usually during

the first few weeks of treatment. If irritation is excessive or persists, use of FINACEA Gel, 15%, should bediscontinued, and patients should consult their physician (See ADVERSE REACTIONS).

• Avoid any foods and beverages that might provoke erythema, flushing, and blushing (including spicy food, alcoholicbeverages, and thermally hot drinks, including hot coffee and tea).

• Patients should report abnormal changes in skin color to their physician.• Avoid the use of occlusive dressings or wrappings.Drug Interactions: There have been no formal studies of the interaction of FINACEA Gel, 15%, with other drugs.Carcinogenesis, Mutagenesis, Impairment of Fertility:Systemic long-term animal studies have not been performed to evaluate the carcinogenic potential of azelaicacid. In a 26-week dermal carcinogenicity study using transgenic (Tg.AC) mice, FINACEA Gel, 15%, and the gelvehicle, when applied once or twice daily, did not increase the number of female Tg.AC animals with papillomasat the treatment site. No statistically significant increase in the number of animals with papillomas at the treatmentsite was observed in male Tg.AC animals after once daily application. After twice daily application, FINACEAGel, 15%, and the gel vehicle induced a statistically significant increase in the number of male animals withpapillomas at the treatment site when compared to untreated males. This suggests that the positive effect may beassociated with the vehicle application. The clinical relevance of the findings in animals to humans is not clear. Azelaic acid was not mutagenic or clastogenic in a battery of in vitro (Ames assay, HGPRT in V79 cells {Chinesehamster lung cells}, and chromosomal aberration assay in human lymphocytes) and in vivo (dominant lethalassay in mice and mouse micronucleus assay) genotoxicity tests.Oral administration of azelaic acid at dose levels up to 2500 mg/kg/day (162 times the maximum recommendedhuman dose based on body surface area) did not affect fertility or reproductive performance in male or female rats. Pregnancy: Teratogenic Effects: Pregnancy Category BThere are no adequate and well-controlled studies of topically administered azelaic acid in pregnant women. Theexperience with FINACEA Gel, 15%, when used by pregnant women is too limited to permit assessment of thesafety of its use during pregnancy.Dermal embryofetal developmental toxicology studies have not been performed with azelaic acid, 15%, gel. Oralembryofetal developmental studies were conducted with azelaic acid in rats, rabbits, and cynomolgus monkeys.Azelaic acid was administered during the period of organogenesis in all three animal species. Embryotoxicity wasobserved in rats, rabbits, and monkeys at oral doses of azelaic acid that generated some maternal toxicity.Embryotoxicity was observed in rats given 2500 mg/kg/day (162 times the maximum recommended human

dose based on body surface area), rabbits given 150 or 500 mg/kg/day (19 or 65 times the maximum recommendedhuman dose based on body surface area) and cynomolgus monkeys given 500 mg/kg/day (65 times the maximumrecommended human dose based on body surface area) azelaic acid. No teratogenic effects were observed in theoral embryofetal developmental studies conducted in rats, rabbits and cynomolgus monkeys.An oral peri- and post-natal developmental study was conducted in rats. Azelaic acid was administered fromgestational day 15 through day 21 postpartum up to a dose level of 2500 mg/kg/day. Embryotoxicity was observedin rats at an oral dose that generated some maternal toxicity (2500 mg/kg/day; 162 times the maximum recommendedhuman dose based on body surface area). In addition, slight disturbances in the post-natal development of fetuseswas noted in rats at oral doses that generated some maternal toxicity (500 and 2500 mg/kg/day; 32 and 162 timesthe maximum recommended human dose based on body surface area). No effects on sexual maturation ofthe fetuses were noted in this study.Because animal reproduction studies are not always predictive of human response, this drug should be usedonly if clearly needed during pregnancy.Nursing Mothers: Equilibrium dialysis was used to assess human milk partitioning in vitro. At an azelaicacid concentration of 25 µg/mL, the milk/plasma distribution coefficient was 0.7 and the milk/buffer distributionwas 1.0, indicating that passage of drug into maternal milk may occur. Since less than 4% of a topically applieddose of azelaic acid cream, 20%, is systemically absorbed, the uptake of azelaic acid into maternal milk is notexpected to cause a significant change from baseline azelaic acid levels in the milk. However, caution shouldbe exercised when FINACEA Gel, 15%, is administered to a nursing mother.Pediatric Use: Safety and effectiveness of FINACEA Gel, 15%, in pediatric patients have not been established.Geriatric: Clinical studies of FINACEA Gel, 15%, did not include sufficient numbers of subjects aged 65 and over todetermine whether they respond differently from younger subjects.ADVERSE REACTIONSOverall, treatment related adverse events, including burning, stinging/ tingling, dryness/tightness/ scaling, itching,and erythema/irritation/ redness, were 19.4% (24/124) for FINACEA Gel, 15%, and 7.1% (9/127) for the activecomparator gel at 15 weeks. In two vehicle controlled, and one active controlled U.S. clinical studies, treatment safety was monitored in 788patients who used twice daily FINACEA Gel, 15%, for 12 weeks (N=333) or for 15 weeks (N=124), or the gelvehicle (N=331) for 12 weeks.

Table 3. Cutaneous Adverse Events Occurring in ≥1% of Subjects in the Rosacea Trials by Treatment Groupand Maximum Intensity*

FINACEA Gel, 15% Vehicle N=457 (100%) N=331 (100%) Mild Moderate Severe Mild Moderate Severe n=99 n=61 n=27 n=46 n=30 n=5 (22%) (13%) (6%) (14%) (9%) (2%) Burning/ stinging/ tingling 71 (16%) 42 (9%) 17 (4%) 8 (2%) 6 (2%) 2 (1%) Pruritus 29 (6%) 18 (4%) 5 (1%) 9 (3%) 6 (2%) 0 (0%) Scaling/dry skin/xerosis 21 (5%) 10 (2%) 5 (1%) 31 (9%) 14 (4%) 1 (<1%) Erythema/ irritation 6 (1%) 7 (2%) 2 (<1%) 8 (2%) 4 (1%) 2 (1%) Contact dermatitis 2 (<1%) 3 (1%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) Edema 3 (1%) 2 (<1%) 0 (0%) 3 (1%) 0 (0%) 0 (0%) Acne 3 (1%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%)

*Subjects may have >1 cutaneous adverse event; thus, the sum of the frequencies of preferred terms mayexceed the number of subjects with at least 1 cutaneous adverse event.FINACEA Gel, 15%, and its vehicle caused irritant reactions at the application site in human dermal safety studies.FINACEA Gel, 15%, caused significantly more irritation than its vehicle in a cumulative irritation study. Someimprovement in irritation was demonstrated over the course of the clinical studies, but this improvement mightbe attributed to subject dropouts. No phototoxicity or photoallergenicity were reported in human dermal safetystudies.In patients using azelaic acid formulations, the following additional adverse experiences have been reportedrarely: worsening of asthma, vitiligo depigmentation, small depigmented spots, hypertrichosis, reddening (signsof keratosis pilaris), and exacerbation of recurrent herpes labialis.Post-marketing safety-Skin: facial burning and irritation; Eyes: iridocyclitis on accidental exposure with FINACEAGel, 15%, to the eye (see PRECAUTIONS).

Distributed under license; U.S. Patent No 6,534,070www.myfinacea.com©2010, Intendis, Inc. All rights reserved, July 2010Manufactured by Intendis Manufacturing S.p.A., Segrate, Milan, Italy

Distributed by:Morristown, NJ 07962

6706803BS

Intendis is part of the Bayer Group

Finacea(azelaic acid) Gel,15%

®�

12 · mArcH 2011 An Independent supplement by medIAplAnet to usA todAy

FINACEA is unique – it is the first and only FDA-approved gel for treating the bumps, pimples and associated redness of mild to moderate rosacea.

Ask your healthcare professional if FINACEA is right for you!

INDICATION & USAGEFINACEA is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated.

IMPORTANT SAFETY INFORMATIONFINACEA is for dermatologic use only, and not for ophthalmic, oral, or intravaginal use. FINACEA is contraindicated in individuals with a history of hypersensitivity to propylene glycol or any other component of the formulation. In clinical trials, sensations of burning/stinging/tingling occurred in 29% of patients, and itching in 11%, regardless of the relationship to therapy. Post-marketing safety - Skin: facial burning and irritation; Eyes: iridocyclitis on accidental exposure to the eye. There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with a dark complexion, these patients should be monitored for early signs of hypopigmentation.

Other than FINACEA, Intendis, Inc. (part of the Bayer group) does not promote or endorse any products or recommendations made by third parties. All products and brand names listed are the property and responsibility of their respective trademark and copyright holders.

Intendis, Inc. reserves the right to terminate or modify this program at its sole discretion and without notice.

Please see full Prescribing Information for FINACEA at www.MyFinacea.com.See Brief Summary of patient prescribing information on reverse page.You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-888-INFO-FDA

Take control of managing your mild to

moderate rosacea with

Visit MyFinacea.com for more information.

Available in March – The Rosacea App! Free for download on iPhone, Blackberry and Android.

FREE

11-F

IN-J

A-0

02 |

Mar

ch 2

011

FINACEA is a registered trademark of Intendis, Inc. ©2011 Intendis, Inc. All rights reserved.

is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Although some was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy

FINACEA Ad - USA Today9.75 X 10.25